Active Systemic Lupus Erythematosus
Conditions
Brief summary
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in Asian participants with active systemic lupus erythematosus (SLE).
Detailed description
This is a Phase III, multicenter, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of an intravenous treatment regimen of 300 mg anifrolumab versus placebo in participants with moderate to severe, autoantibody positive SLE while receiving SOC treatment. The study will be performed in participants aged 18 to 70 years of age. Participants with a confirmed diagnosis of moderate to severe active SLE and are currently receiving SOC comprising of oral corticosteroids (OCSs) and/or antimalarial, and/or immunosuppressants, either alone or any combination of them, for a required duration of treatment at a stable dose, as described in the inclusion criteria shall be included. Participants must have eligible scores for SLEDAI-2K, BILAG-2004, and PGA as confirmed by the DACRT. Eligible participants will be randomised in a 1:1 ratio to receive either a fixed intravenous dose of 300 mg anifrolumab plus SOC or placebo plus SOC every 4 weeks (Q4W) for a total of 13 doses (Week 0 to Week 48), with the primary endpoint evaluated at the Week 52 visit.
Interventions
BIOLOGICALAnifrolumab
Intravenous infusion (IV)
DRUGplacebo
Intravenous infusion (IV)
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
double blind
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Key inclusion criteria: 1. Aged 18 to 70 years. 2. Body weight ≥ 40 kg. 3. Confirmed diagnosis of SLE(1997 ACR revised criteria) for ≥ 24 weeks. 4. Must be receiving at least one of the following SOC regimens at screening: 1. oral prednisone monotherapy: ≥ 7.5 mg/day and ≤ 40 mg/day, stable for \> 2 weeks; 2. Immunosuppressant(s) with or without OCS and must be stable for ≥ 8 weeks; 3. Oral prednisone plus immunosuppressant: start date, stability and maximum dose required. 5. At least one of these antibodies positive: ANA, anti-dsDNA and anti-Smith. 6. SLEDAI-2K score ≥ 6 points at screening and "Clinical" SLEDAI-2K score ≥4 points at both screening and Day1(randomisation), and BILAG with at least 1 level A organ system or 2 level B organ system, and PGA score ≥ 1.0 at screening. 7. Chest imaging shows no clinically significant abnormalities (unless due to SLE). 8. No evidence or medical history of active TB, indeterminate TB should be referred to a TB specialist. 9. All participants should use effective contraception methods as protocol requests. 10. Any negative SARS-CoV-2 RT-PCR test result at screening and no known or suspected COVID-19 infection or exposure within 2 weeks prior to screening and between screening and randomisation visits. Key
Exclusion criteria
1. History or current diagnose of clinically significant non-SLE related vasculitis, severe or unstable neuropsychiatric SLE, active severe SLE-driven renal disease, catastrophic anti-phospholipid syndrome, inflammatory joint or skin disease other than SLE, non-SLE disease that has required treatment of certain dosage of corticosteroid. 2. History or evidence of suicidal ideation or suicidal behavior. 3. History or current diagnose of MTCD or overlap syndrome, unless overlap with RA or MTCD which has developed into SLE. 4. History of recurrent infection requiring hospitalization and IV antibiotics, or opportunistic infection requiring hospitalization or IV antimicrobial treatment within 3 years of randomization, or clinically significant chronic infection within 3 months, or recent infection still under treatment. 5. History of immunodeficient condition, HIV positive included. 6. Confirmed HBsAg positive, or HBcAb positive and HBV DNA detectable, or hepatitis C antibody positive. 7. History of severe case of herpes zoster. 8. Herpes zoster, CMV or EB infection which has not completely resolved within 12 weeks before screening. 9. Acute COVID-19 infection or history of severe COVID-19. 10. History of cancer, apart from cured squamous or basal cell carcinoma and cervical cancer in situ. 11. Female participants with abnormal pap smear results. 12. Prior receipt of anifrolumab ,or any commercially available Janus kinase (JAK) inhibitor ≤ 12 weeks or Bruton's tyrosine kinase (BTK) inhibitor ≤ 24weeks prior to signing the ICF; any investigational medicinal product(small molecule or biologic agent) within 4 weeks or 5 half-lives prior to signing of the ICF, whichever is greater. 13. Known history of allergy to any component of the IP formulation or protein related products. 14. Receipt of any of the following: 1. Intramuscular or IV glucocorticosteroids within 6 weeks; 2. Any live or attenuated vaccine within 8 weeks; 3. Any restricted medication listed in protocol; 4. Blood transfusion within 4 weeks. 15 Regular use of \> 1 NSAID within 2 weeks or receipt of fluctuating doses of a NSAID within 2 weeks. 16\. Certain laboratory test results requirements. 17. Concurrent enrolment in another clinical study. 18. History or current alcohol, drug or chemical abuse within 1 year. 19. Major surgery within 8 weeks or planned elective major surgery.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo | Week 52 | Composite endpoint (BICLA),a composite binary endpoint defined by meeting all of the following criteria: * Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, where worsening is defined as ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B * No worsening from baseline in SLEDAI-2K, where worsening is defined as an increase from baseline of \>0 points in SLEDAI-2K * No worsening from baseline in participants' lupus disease activity, where worsening is defined as an increase of ≥0.30 points on a 3-point PGA visual analogue scale (VAS) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The Proportion of Participants Who Achieve SRI(4) Response at Week 52 | Week 52 | SRI(4) response defined by meeting all of the following criteria: * Reduction from baseline of ≥ 4 points in the SLEDAI-2K; * No new organ systems affected as defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items compared to baseline; * No worsening from baseline in the participants' lupus disease activity defined by an increase ≥0.30 points on a 3-point PGA VAS; |
| The Proportion of Participants Who Achieve an Oral Corticosteroid (OCS) Dose ≤7.5 mg/Day at Week 40, Which is Maintained Through Week 52 in the Subgroup of Those With Baseline OCS ≥10 mg/Day | Week 52 | Maintained OCS reduction defined by meeting all of the following criteria: * Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 * Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52 |
| Annualized Flare Rate Through Week 52 | Week 52 | Annualised flare rate with flare defined as either 1 or more new BILAG-2004 A or 2 or more new BILAG-2004 B items compared to the previous visit |
Countries
China, Hong Kong, Philippines, South Korea, Taiwan, Thailand
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 36.1 Years STANDARD_DEVIATION 9.8 |
| Age, Customized Age group >=18 to <65 years | 274 Participants |
| Age, Customized Age group >=65 years | 2 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 138 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 138 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 0 Participants |
| Sex: Female, Male Female | 254 Participants |
| Sex: Female, Male Male | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 138 | 0 / 138 |
| other Total, other adverse events | 119 / 138 | 115 / 138 |
| serious Total, serious adverse events | 30 / 138 | 17 / 138 |
Outcome results
None listed